Novo Nordisk’s chief executive Lars Fruergaard Jørgensen has agreed to appear at a Senate hearing later this year to defend the pricing of the group’s semaglutide-based therapies for diabetes and obesity.Jorgensen’s decision was revealed in a statement from Sen Bernie Sanders (I-Vt), who had threatened to subpoena the company to force Novo Nordisk’s North America operations chief Doug Langa to be available to answer questions at the Health, Education, Labor and Pensions (HELP) committee hearing in early September.
